Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Non-Current Assets (2017 - 2025)

Protagonist Therapeutics' Non-Current Assets history spans 9 years, with the latest figure at $11.7 million for Q4 2025.

  • For Q4 2025, Non-Current Assets fell 7.28% year-over-year to $11.7 million; the TTM value through Dec 2025 reached $11.7 million, down 7.28%, while the annual FY2025 figure was $11.7 million, 7.28% down from the prior year.
  • Non-Current Assets for Q4 2025 was $11.7 million at Protagonist Therapeutics, down from $115.3 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $136.3 million in Q1 2025 and bottomed at $1.7 million in Q1 2024.
  • The 5-year median for Non-Current Assets is $9.3 million (2021), against an average of $35.0 million.
  • The largest annual shift saw Non-Current Assets tumbled 87.78% in 2022 before it soared 7809.0% in 2025.
  • A 5-year view of Non-Current Assets shows it stood at $7.0 million in 2021, then plummeted by 33.52% to $4.6 million in 2022, then plummeted by 53.55% to $2.1 million in 2023, then surged by 486.64% to $12.6 million in 2024, then decreased by 7.28% to $11.7 million in 2025.
  • Per Business Quant, the three most recent readings for PTGX's Non-Current Assets are $11.7 million (Q4 2025), $115.3 million (Q3 2025), and $115.5 million (Q2 2025).